Investor Relations

Investor Relations

Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Leadership Team Board of Directors
Recent News
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
Nov 16, 2023

--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that...

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
Nov 15, 2023

—CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition— —CM-101's Phase 2 SPRING Trial in PSC is Advancing...

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
Nov 13, 2023

—New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101— —Oral...

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 9, 2023

—Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 2024— —Reiterates Guidance that Cash...

All News

Stock Info
NASDAQCMMB
Events
American College of Rheumatology Convergence 2023 – San Diego, CA, Nov.10-15, 2023
Tuesday, November 14, 2023
9:00am - 11:00am PST

Date: Nov. 14, 2023
Time: 9:00-11:00 am PT
Format: Poster presentation: The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Presenter: Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics
Authors: Itzchak Amoyal, Tzipi Hornik-Lurie, Tali Zitman-Gal, Hilit Levy, Ilan Vaknin Liat Drucker, Ishai Heusler, Yair Levy, Shelly Tartakover Matalo
Session: Poster Session C, Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science
Information: rheumatology.org/annual-meeting

AASLD The Liver Meeting® 2023, Boston, MA, Nov. 10-14, 2023
Monday, November 13, 2023
4:30pm EST

Date: Nov. 13, 2023
Time: 4:30pm ET
Format: Oral presentation: Serum proteomics reveals unique association of CCL24 with disease-related pathways and signatures in primary sclerosing cholangitis
Presenter: Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics, Ltd.
Authors: Tom Snir, Raanan Greenman, Revital Aricha, John Lawler, Francesca Saffioti, Douglas Thorburn, Massimo Pinzani, Adi Mor, Ilan Vaknin
Session: Room 312 - Breaking the Chains of Cholestatic Liver Injury: Advancements and Promising Treatment Strategies
Information: The Liver Meeting | AASLD

All Events

Featured Presentations

Download

Chemomab Corporate Overview - November 2023

 

Annual Report

Download

Chemomab 2022 Annual Report